Evotec SE Announces Supervisory Board Nomination and Tubulis Acquisition Proceeds

Evotec SE has announced two significant updates. Firstly, the company has nominated Dieter Weinand, a seasoned industry veteran with over 30 years of global pharmaceutical leadership experience, to be the Chairman of the Supervisory Board. This nomination, proposed for election at the upcoming Annual General Meeting, aims to strengthen the board's leadership in areas crucial for Evotec's transformation, including commercial execution, strategic partnerships, and profitability. Mr. Weinand's extensive experience includes leadership roles at major pharmaceutical companies and current board memberships. Secondly, Evotec is set to receive approximately $100 million in upfront consideration from the sale of its equity stake in Tubulis GmbH to Gilead Sciences. This transaction, which is part of Evotec's portfolio monetization strategy, may also include up to an additional $58 million in contingent consideration. Evotec had initially invested in Tubulis during its Series B financing rounds in 2022 and 2024, and Tubulis currently has two clinical-stage programs targeting solid tumors.